Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes. [PDF]
Liao KM, Wu JY, Lai CC.
europepmc +1 more source
High‐Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy
Abstract Background Multiple system atrophy (MSA) is a rare and devastating neurodegenerative disorder. Accumulating clinical and preclinical evidence suggests that diabetes and insulin resistance may adversely influence MSA pathophysiology. Objective We investigated the potential association between diabetes, impaired glucose homeostasis, and MSA ...
Marie‐Laure Arotcarena +7 more
wiley +1 more source
Abstract Gastrointestinal dysfunction is increasingly recognized as a core feature of Parkinson's disease (PD), affecting quality of life, nutrition, medication response, and potentially the earliest stages of pathogenesis. This perspective traces the evolution of the gut from a neglected source of non‐motor symptoms to a central component of ...
Filip Scheperjans +4 more
wiley +1 more source
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Obesity is a chronic disease associated with multiple health risks. Multimodal treatments including lifestyle interventions, pharmacotherapies and bariatric surgery should be the standard of care for obesity management. Bariatric surgery remains the most
Kaivalya ABBURI (22136206) +3 more
core +1 more source
Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes. [PDF]
Chebi P +8 more
europepmc +1 more source
Weight Loss Intentionality and Strategies in Urinary Incontinence
ABSTRACT Introduction Urinary incontinence (UI)−including stress (SUI), urge (UUI), and mixed (MUI) subtypes−is associated with obesity, and weight loss is commonly recommended for intervention. However, the comparative effects of intentionality and weight loss strategies on UI severity remain poorly defined.
Eric S. Chai +7 more
wiley +1 more source
Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. [PDF]
Venne JL +5 more
europepmc +1 more source
Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques +4 more
wiley +1 more source
Introduction to virtual special issue on glucagon-like peptide-1 agonists and the skin. [PDF]
Levin NA.
europepmc +1 more source
Multifaceted burden of short bowel syndrome for patients and caregivers: The landmark survey
Abstract Background Short bowel syndrome is a debilitating condition often requiring long‐term parenteral support to maintain hydration, nutrition, and survival. Methods As part of the noninterventional, cross‐sectional Landmark Survey study, we evaluated burdens associated with short bowel syndrome and parenteral support dependency from patient and ...
Jenny E. Harrison +11 more
wiley +1 more source

